Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the United States

References

• American Diabetes Association (ADA). Standards of medical care in diabetes—2020; 2020 [cited 2022 May 16]. Available from: https://diabetesjournals.org/clinical/article/38/1/10/32237/Standards-of-Medical-Care-in-Diabetes-2020.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). National diabetes statistics report; 2020 [cited 2021 March 29]. Available from: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf.
   Google Scholar
• International Diabetes Federation (IDF). Diabetes and cardiovascular disease. Brussels: IDF; 2016. p. 1–144.
   Google Scholar
• International Diabetes Federation (IDF). IDF diabetes atlas. 7th ed. Brussels: IDF; 2015.
   Google Scholar
• Sarwar N, Gao P, Seshasai SR, Emerging Risk Factors Collaboration, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Emerging risk factors collaboration. Lancet. 2010;375(9733):2215–2222.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018a;17(1):83.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Acs A, Ludwig C, et al. Economic burden of cardiovascular disease in type 2 diabetes: a systematic review. Value Health. 2018b;21(7):881–890.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes—2017. Diabetes Care. 2017;40(Suppl 1):S1–S135.
   PubMedGoogle Scholar
• Arnold SV, de Lemos JA, Rosenson RS, GOULD Investigators, et al. Use of guideline-recommended risk reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease. Insights from getting to an improved understanding of low-density lipoprotein cholesterol and dyslipidemia management (GOULD). Circulation. 2019;140(7):618–620.
   PubMed Web of Science ®Google Scholar
• Hamid A, Vaduganathan M, Oshunbade AA, et al. Antihyperglycemic therapies with expansions of US food and drug administration indications to reduce cardiovascular events: prescribing patterns within an academic medical center. J Cardiovasc Pharmacol. 2020;76(3):313–320.
   PubMed Web of Science ®Google Scholar
• Pantalone KM, Misra-Hebert A, Hobbs TM, et al. Antidiabetic treatment patterns and specialty care among patients with type 2 diabetes and cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):54.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Charlson RE, Peterson JC, et al. The charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008;61(12):1234–1240.
   PubMed Web of Science ®Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619.
   PubMed Web of Science ®Google Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682.
   PubMed Web of Science ®Google Scholar
• Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care. 2008;14:15–23.
   PubMed Web of Science ®Google Scholar
• Glasheen WP, Renda A, Dong Y. Diabetes complications severity index (DCSI) – update and ICD-10 translation. J Diabetes Complic. 2017;31(6):1007–1013.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, EMPA-REG OUTCOME Investigators, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, CANVAS Program Collaborative Group, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, LEADER Steering Committee; LEADER Trial Investigators, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016a;375(4):311–322.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, SUSTAIN-6 Investigators, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016b;375(19):1834–1844.
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Green JB, Janmohamed S, Harmony Outcomes committees and investigators, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomized placebo-controlled trial. Lancet. 2018;392(10157):1519–1529.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, REWIND Investigators, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, ELIXA Investigators, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257.
   PubMed Web of Science ®Google Scholar
• Holman RR, Bethel MA, Mentz RJ, EXSCEL Study Group, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–1239.
   PubMed Web of Science ®Google Scholar
• Luo J, Feldman R, Rothenberger SD, et al. Coverage, formulary restrictions, and out-of-pocket costs for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in the Medicare part D program. JAMA Netw Open. 2020;3(10):e2020969.
   PubMed Web of Science ®Google Scholar
• Sola D, Rossi L, Schianca GPC, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;11(4):840–848.
   PubMed Web of Science ®Google Scholar
• Newman TV, Munshi KD, Neilson LM, et al. Health care utilization and costs associated with switching from DPP-4i to GLP-1 RA or SGLT2i: an observational cohort study. J Manag Care Spec Pharm. 2021;27(4):435–443.
   PubMed Web of Science ®Google Scholar
• Blonde L, Aschner P, Bailey C, Global Partnership for Effective Diabetes Management, et al. Gaps and barriers in the control of blood glucose in people with type 2 diabetes. Diab Vasc Dis Res. 2017;14(3):172–183.
   PubMed Web of Science ®Google Scholar
• Adhikari R, Blaha M. New insights into prescribing of SGLT2 inhibitors and GLP-1 receptor agonists by cardiologists in 2020: major barriers limiting role. 2021 [cited 2022 June 10]. Available from: https://www.acc.org/latest-in-cardiology/articles/2021/01/19/14/27/new-insights-into-prescribing-of-sglt2-inhibitors-and-glp-1-receptor-agonists-in-2020#.YAr3dDQXc0Y.twitter.
   Google Scholar